Shantha Biotechnics
Welcome to MedLibrary.org. For best results, we recommend beginning with the navigation links at the top of the page, which can guide you through our collection of over 14,000 medication labels and package inserts. For additional information on other topics which are not covered by our database of medications, just enter your topic in the search box below:
| Industry | Biotechnology, Vaccines |
|---|---|
| Founded | 1993 |
| Founder(s) | K I Varaprasad Reddy |
| Headquarters | Medchal, Hyderabad (India) |
| Key people |
K I Varaprasad Reddy Chairman of the Board, Harish Iyer, Chief Executive Officer |
| Products | recombinant DNA vaccines |
| Parent | Sanofi |
| Website | Shanthabiotech.com |
Shantha Biotechnics is an Indian biotechnology company based in Hyderabad. It is the first Indian company to develop, manufacture and market a recombinant human healthcare product in India. The company is a wholly owned Subsidiary of Sanofi group.[1]
Contents |
History
The genesis of Shantha Biotechnics Ltd can be traced back to the initiatives of Dr. K I Varaprasad Reddy and Mr. Khalil Ahmed; Dr. Varaprasad and Mr. Khalil Ahmed established the company in 1993 with the sole purpose of developing efficacious but cost effective vaccines and therapeutics.[1]
The project began modestly as an R&D outfit at the Osmania University under the industry-university interactive programme in 1993 and later at the Center for Cellular and Molecular Biology until an independent R&D facility was built.
In 2009, French pharma major Sanofi vaccine division Sanofi Pasteur has acquired Hyderabad-based Shantha Biotechnics, which has been valued at euro 550 million (over Rs 3,770 crore).[2]
See also
References
- ^ a b "Shantha Biotech to launch 5-in-1 pediatric vaccine - CNBC-TV18". Moneycontrol.com. Retrieved 2012-09-28.
- ^ Somashekar Mulugu. "Business Line : Companies News : Top level changes at Shantha Biotechnics". Thehindubusinessline.com. Retrieved 2012-09-28.
